Strawberry Fields REIT (NYSE:STRW) completed the acquisition of a healthcare campus in Marshall, Missouri, adding a 60-bed hospital, a 99-bed skilled nursing facility, and a medical office building to its portfolio.
Summit Therapeutics (NASDAQ:SMMT) reported updated overall survival results from the global Phase III HARMONi clinical trial showing ivonescimab plus chemotherapy continued to demonstrate survival results in patients with EGFR-mutated advanced non-small cell lung cancer.
Allarity Therapeutics (NASDAQ:ALLR) received a Japanese patent for its stenoparib-specific DRP companion diagnostic, covering methods to identify patients likely to benefit from stenoparib treatment.
Abbott (NYSE:ABT) agreed to pay $385 million on September 14, 2026, to resolve government and civil claims connected to its 2022 powdered infant formula recall.
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to sell its DePuy Synthes orthopedics business to Apollo Global Management for approximately $20 billion.
Biofrontera (NASDAQ:BFRI) received U.S. FDA approval of a supplemental New Drug Application for its Ameluz 10% topical gel and BF-RhodoLED lamp to treat adult patients with superficial basal cell carcinoma.
Amgen (NASDAQ:AMGN) received U.S. FDA approval to update the prescribing information for IMDELLTRA, reducing the initial monitoring time to 6–8 hours.
Pasithea Therapeutics (NASDAQ:KTTA) announced that it will present initial clinical data from Part A of its ongoing Phase 1/1b trial evaluating PAS-004 in adults with neurofibromatosis type 1 (NF1).
Corbus Pharmaceuticals (NASDAQ:CRBP) reported Phase 1b data showing a 5% mean weight loss with CRB-913 after 12 weeks.
Definium Therapeutics (NASDAQ:DFTX) reported positive topline results from the Phase 3 Panorama study evaluating DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder.
Phio Pharmaceuticals (NASDAQ:PHIO) submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration to support the next phase of development for its INTASYL siRNA candidate PH-762.
Telix (NASDAQ:TLX) received U.S. Food and Drug Administration approval for Pixclara, or floretyrosine F 18, as a PET imaging drug for evaluating glioma.
